The Danish biotech company Evaxion Biotech A/S has decided to complete a follow-on public offering (FPO) on Nasdaq in the US.
3,942,856 ADSs are issued at a price of USD 7 per ADS. The gross proceeds are approx. USD 27.6 million.
Evaxion Biotech A/S has invented a technology using algorithms to identify the mutations in cancer tumours that cause the immune system of the human body to react and combat the cancer. The result is an immunotherapy tailored for the individual patient.
The company was formed in 2008, and the ambition is to become the global leader in cancer therapy based on artificial intelligence.
Accura advised Oppenheimer & Co. Inc. in their capacity as sole bookrunner on Evaxion Biotech A/S’s follow-on public offering.
Accura was also local counsel for Oppenheimer & Co. when the company acted as lead underwriter in connection with the original ADS listing.